Syngene Q1 FY26 Earnings Results

Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. The company serves emerging, mid and large sized Bio-Pharma companies, Animal Healthcare companies, Agrochemical companies, consumer products companies etc. Its clientele includes Amgen, J&J, GSK, Merck, Sanofi, Bayer, FMC, Unilever among others. Presenting below are its Q1 FY26 earnings results.

 

Q1 FY26 Earnings Results

• Revenue: ₹875 crore, up 11% year-over-year (YoY) from ₹790 crore in Q1 FY25.

• Net Profit (PAT): ₹87 crore, an increase of 14% YoY from ₹76 crore last year.

• EBITDA: ₹206 crore, up 19% YoY, with an EBITDA margin of 25%, compared to 23% a year ago.

• EPS: Approximately ₹2.15.

• Operational Highlights: Strong performance driven by conversion of pilot programs into longer-term contracts in the Research Services business.

• Manufacturing Update: Syngene’s Bengaluru Unit III facility has started operations with the first clinical batch delivered. Preparations are underway to launch the Bayview facility in the US later in FY26.

• Other Highlights: USFDA’s GCP inspection of the Human Pharmacology Unit completed with no observations. Over 20 client and regulatory audits successfully completed during the quarter.

 

Management Commentary & Strategic Highlights

• CEO Peter Bains highlighted a very positive start to FY26, emphasizing confidence about maintaining guidance for the year.

• The research services segment is seeing strong momentum with high conversion rates from pilot projects to larger contracts.

• Manufacturing expansion through new facilities supports long-term growth.

• Despite macroeconomic headwinds, management is optimistic on sustaining revenue growth and profitability.

• Tax benefits relating to gratuity funds contributed to profit in the quarter.

 

 

Q4 FY25 Earnings Results

• Revenue: ₹1,016 crore, up by 11 percent on the YoY basis.

• Net Profit: ₹183 crore, down by 3 percent over the same period during last year.

• EBITDA: ₹344 crore, with 25.5% margin.

• FY25 Q4 set a strong base as the company expanded capacity and deepened client engagement.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.